Tivic Health Systems, Inc.

Tivic Health Systems, Inc. is a U.S.-based therapeutics company built around two platforms: bioelectronic medical devices and TLR5-based immunotherapeutics. Its current commercial product is ClearUP, an FDA-cleared over-the-counter device for sinus pain, pressure, and congestion, while its development pipeline includes non-invasive vagus nerve stimulation and Entolimod for radiation injury and oncology-related indications.

52

20.13

19.57

— Tivic Health Systems, Inc.
%
Consumer bioelectronic device100% ClearUP and related accessories sold for sinus pain, pressure, and congestion relief.
Non-invasive vagus nerve stimulation0% Development-stage bioelectronic systems intended to modulate autonomic and neurologic pathways.
TLR5 immunotherapeutics0% Drug candidates centered on Entolimod and related TLR5 agonist programs for radiation and oncology uses.

Tivic sells ClearUP to consumers directly online and through large retail and distribution channels, including...

  • Direct-to-consumer ClearUP usersprimary

    Individuals buying the FDA-cleared sinus relief device online for self-treatment of congestion and pressure.

  • Reseller and distributor channelsprimary

    Medical supply and retail partners that stock ClearUP and sell it through their own channels.

  • Clinical and institutional therapeutics buyersemerging

    Hospitals, clinical trial sites, and future specialty buyers for Entolimod and related programs.

  • Government and radiation-injury end marketsemerging

    Potential purchasers or users of Entolimod for acute radiation syndrome and related emergency indications.

Tivic is headquartered in the United States and its commercial activity is centered there through direct online sales...

  • •Headquartered in the United States
  • •ClearUP sold through U.S. online and retail channels
  • •FDA-regulated development programs are centered in the U.S.
  • •Clinical research partnerships support U.S.-based VNS work
  • •Future therapeutics commercialization is expected to begin in the U.S.

Tivic's strategy is to wind down the consumer ClearUP business and reallocate resources toward its biopharmaceutical...

01
Advance Entolimod developmentshort-term

The TLR5 program is the main long-term value driver and potential future revenue source.

02
Exit or monetize ClearUPshort-term

The company is reducing reliance on consumer device sales to focus capital on therapeutics.

03
Refine VNS indication strategymedium-term

Targeting the most commercially attractive indications improves the odds of clinical and market success.

04
Build a biopharmaceutical operating capabilitymedium-term

Drug development requires clinical, regulatory, and manufacturing capabilities beyond consumer devices.

Tivic faces execution risk from its transition away from consumer device sales toward clinical-stage therapeutics,...

high

Wind-down of the ClearUP business

Consumer sales currently generate the company's revenue, so exiting the business can sharply reduce top-line support.

Scope
ClearUP revenue and brand visibility
Materiality
high
high

Clinical and regulatory failure in Entolimod

Drug candidates can fail in preclinical or clinical testing, and regulatory pathways may not lead to approval.

Scope
TLR5 program, ARS, neutropenia, oncology indications
Materiality
high
high

Liquidity and financing dependence

The company has historically funded operations through securities issuance and continues to burn cash.

Scope
Ongoing R&D and corporate operations
Materiality
high
medium

Commercial adoption risk for VNS

Non-invasive neuromodulation must prove clinical utility, payer acceptance, and market fit across target indications.

Scope
Non-invasive vagus nerve stimulation
Materiality
medium
medium

Third-party supply chain and outsourcing dependence

Manufacturing, clinical, and administrative functions rely heavily on external vendors and partners.

Scope
ClearUP production and development programs
Materiality
medium
Inventory reserves
Can affect cost of sales and gross profit
Sales return reserves
Affects reported net revenue
Stock-based compensation
Affects operating expenses and net loss
Going concern
Important for financial statement interpretation

electroCore, Inc.

ECOR · Electromedical & Electrotherapeutic Apparatus

LivaNova PLC

LIVN · Electromedical & Electrotherapeutic Apparatus

TACTILE SYSTEMS TECHNOLOGY INC

TCMD · Surgical & Medical Instruments & Apparatus

Neuraxis, INC

NRXS · Electromedical & Electrotherapeutic Apparatus

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

SIGA TECHNOLOGIES INC

SIGA · Pharmaceutical Preparations

: 29/04/2026